MAP2K7 and hepatocellular carcinoma: Additionally, PRMT6 has been shown to have tumor-promoting properties in different systems, including the blood system (leukemia), the brain system (glioblastoma), etc. However, PRMT6 regulates aerobic glycolytic responses in hepatocellular carcinoma [84], induces autophagic responses in the malignant microenvironment of hepatocellular carcinoma [85], and affects hepatocarcinogenesis and progression by regulating RAS/RAF binding and MEK/ERK signaling pathways [80].